Pulmonary Hypertension Associated With Interstitial Lung Disease clinical trials

Explore recruiting pulmonary hypertension associated with interstitial lung disease clinical trials.

Recruiting pulmonary hypertension associated with interstitial lung disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pulmonary Hypertension Associated With Interstitial Lung Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A PHASE 2A, OPEN-LABEL SINGLE ARM MULTICENTER EXPLORATORY STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF ORAL DOSES OF ROC-101 IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) AND PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (ILD-PH)

Spain, Italy, Poland, France, Latvia, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)

Latvia, Germany, Italy, Czechia, France, Belgium +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term use of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease

Spain, Italy, Germany, Belgium

Phase II and Phase III (Integrated) EU CTIS Study details

A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

Greece, France, Italy, Belgium, Denmark, Germany +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Randomized, Placebo-Controlled Trial to Assess the Efficacy and Safety of Mosliciguat in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease

Netherlands, Italy, Belgium, France, Germany, Czechia +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallelgroup Study to Evaluate the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease

Portugal, Italy, Czechia, Poland, Denmark, Greece +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Pulmonary Hypertension Associated With Interstitial Lung Disease trials by city

Pulmonary Hypertension Associated With Interstitial Lung Disease in Toronto Pulmonary Hypertension Associated With Interstitial Lung Disease in Vancouver Pulmonary Hypertension Associated With Interstitial Lung Disease in Montreal Pulmonary Hypertension Associated With Interstitial Lung Disease in Calgary Pulmonary Hypertension Associated With Interstitial Lung Disease in Edmonton Pulmonary Hypertension Associated With Interstitial Lung Disease in Ottawa Pulmonary Hypertension Associated With Interstitial Lung Disease in Winnipeg Pulmonary Hypertension Associated With Interstitial Lung Disease in Quebec City Pulmonary Hypertension Associated With Interstitial Lung Disease in Hamilton Pulmonary Hypertension Associated With Interstitial Lung Disease in Kitchener Pulmonary Hypertension Associated With Interstitial Lung Disease in London Pulmonary Hypertension Associated With Interstitial Lung Disease in Halifax Pulmonary Hypertension Associated With Interstitial Lung Disease in New York Pulmonary Hypertension Associated With Interstitial Lung Disease in Los Angeles Pulmonary Hypertension Associated With Interstitial Lung Disease in Chicago Pulmonary Hypertension Associated With Interstitial Lung Disease in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease